Trending...
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
- CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
Placed by a Neurosurgeon at the Time of Resection, GammaTile® Therapy Gives Patients a Head STaRT in the Fight Against Brain Tumors, Delaying Tumor Recurrence
TEMPE, Ariz. - PennZone -- GT Medical Technologies, Inc. today announced its GammaTile® Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors will be spotlighted at the 2021 CNS Annual Meeting exhibition October 18-20 in Austin, Texas, and at the 15th Tumor Section Satellite Symposium which immediately precedes it October 15-16.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on The PennZone
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
About GT Medical Technologies, Inc.
More on The PennZone
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on The PennZone
- Winzele: A Trusted Isolation Transformer Manufacturer
- Luxury Mediterranean Estate in Gotha Sells for $1.52 Million, Closing $45,000 Over Asking
- ZEELOOL's Black Friday Sale Starts Early with Up to 80% Off Frames
- UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
- Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
- Focus: Neurosurgical Oncology
- October 15-16 | JW Marriott, Austin Texas
- GT Medical Technologies booth 200
- Saturday, October 16, 12:15 PM-1:15 PM: GammaTile® Therapy: Technology and Device Overview
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
- October 18-20 Exhibits | Austin Convention Center
- GT Medical Technologies booth 1750
About GT Medical Technologies, Inc.
More on The PennZone
- Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
- 2026 Oscars Betting Odds: One Battle After Another Favored for Best Picture
- Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
- Thirteen Reasons Why Gyminny Kids Is San Diego's Best Gymnastics Gym
- Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
Source: GT Medical Technologies
Filed Under: Health
0 Comments
Latest on The PennZone
- Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
- 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
- Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
- Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes
- Diamond Wealth Advisors Experience the New York Stock Exchange and Ring the Closing Bell
- $114.6 Million in Revenues, Up 54%: Uni-Fuels Holdings (N A S D A Q: UFG) Accelerates Global Expansion Across Major Shipping Hubs as Demand Surges
- Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
- TradingHabits.com Launches to Support Day Trader Well-being
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- SMS Launches Real-Time Fiber-Optic Monitoring for Critical Infrastructure
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- LATO AI Tailors AI-Powered Appointment Booking System for Custom Clothing Designer David Alan
- BITE Data raises $3m to build AI tools for global trade compliance teams
- Phinge Issues Notice of Possible Infringement, Investigates App-less AI Agents & Technology for Unauthorized Use of its Patented App-less Technologies
- Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
- CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
- purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
- WHES Retains BloombergNEF Tier 1 Ranking for Sixth Consecutive Quarter
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- UK Financial Ltd Confirms All 8 Mexican Gold Mines Exist — Audited and Backing UKFL's Ecosystem With Double the 2018 Gold Value
